LipoMedix

Company Overview

Snapshot

Founded in June 2011 by Al Gabizon and Rami Kremien, LipoMedix operates with 1–10 employees. The company has secured $56K in total capital across one funding round. In July 2019, LipoMedix received a grant from the European Commission.

Business overview

LipoMedix Pharmaceuticals is a development-stage company focused on innovative, safe, and effective cancer therapy. The company's core technology involves a liposome delivery system, with its lead product, Promitil, demonstrating antitumor effects in various tumor models. LipoMedix operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, targeting the pharmaceutical industry with its cancer therapeutics.

Strategic signal

In January 2020, LipoMedix announced the publication of positive Phase 1 data for its lead product, Promitil (PL-MLP), in the research journal Investigational New Drugs. This publication provides significant scientific validation for the company's liposome-based cancer therapy, signaling to investors and the industry the potential efficacy and safety of Promitil as it progresses through clinical development.

Company Intelligence Q&A

What is LipoMedix's primary focus?

LipoMedix is focused on developing an innovative, safe, and effective cancer therapy based on liposome delivery. Its lead product, Promitil, has shown promising antitumor effects in various tumor models.

When was LipoMedix founded and by whom?

LipoMedix was founded in June 2011 by Al Gabizon and Rami Kremien.

What was a significant recent development for Promitil?

In January 2020, LipoMedix announced the publication of positive Phase 1 data for Promitil (PL-MLP) in the research journal Investigational New Drugs.

Has LipoMedix initiated any clinical trials for Promitil?

In March 2019, LipoMedix announced the initiation of a Phase 1b trial (LIPORAD-2018) for Promitil in combination with radiotherapy in patients with advanced cancer.

What was a notable funding event for LipoMedix?

In July 2019, LipoMedix received a grant of $56K from the European Commission. This non-equity funding was provided by the European Commission.